 |
 Play Video: The Importance of Insider Buying
|
|
|
| Date | Insider | Price | Amount |
|---|
8-29-2023
Insider Buy |
David Weill
|
$62.00
CAGR »
|
$155,000.00
2,500 shares |
11-29-2021
Insider Buy |
Edwin M. Kania Jr.
Director |
$22.56
CAGR »
|
$2,256,215.34
100,000 shares |
11-11-2019
Insider Buy |
David Weill
Director |
$17.00
CAGR »
|
$170,000.00
10,000 shares |
5-6-2019
Insider Buy |
Edward M. Basile
Director |
$16.00
CAGR »
|
$136,000.00
8,500 shares |
5-6-2019
Insider Buy |
Edwin M. Kania Jr.
Director |
$16.00
CAGR »
|
$533,328.00
33,333 shares |
Also See: Institutional Holders of TMDX
Also See: SEC filings
Below we present the annualized performance delivered by TransMedics Group stock since 8-29-2023 (the date of the most recent
insider purchase). The performance of the investment from the time TransMedics Group insider buying occurred is the ultimate
test of whether insiders were right about TMDX being a good buy.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
08/30/2023 |
|
| End date: |
05/03/2024 |
|
| Start price/share: |
$65.35 |
|
| End price/share: |
$127.99 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
95.85% |
|
| Annualized Gain: |
141.65% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$19,585.00 |
|
| Years: |
0.68 |
|
TransMedics Group Insider Buying
This Holdings Channel page has presented insider buying activity, covering Directors, officers (such as CEO, CFO, COO, etc.),
and >10% owners (who are required to file form 4's with the SEC). Important institutional owners may not fall under these
categories, but instead file their holdings quarterly on the latest form 13F filings.
While recent TransMedics Group insider buying activity is included, there may also be stock sales over this same period (Also See: SEC filings for sales and other details).
Also See: Funds Holding TMDX
|
|
Free TMDX Email Alerts:
